Kairos Pharma, LTD

Kairos Pharma and Bayer are collaborating to investigate the combination of ENV-105 and XOFIGO for metastatic prostate cancer.

Kairos Pharma announced compelling interim safety data from its Phase 1 trial of ENV-105 in combination with osimertinib for advanced EGFR-mutated lung cancer patients, showing zero Grade 3+ toxicities.

Kairos Pharma Ltd. announced the results of its 2026 annual meeting of stockholders, where shareholders approved director elections, auditor ratification, a reverse stock split, executive compensation, and amendments to the equity incentive plan.

Kairos Pharma provides a mid-year update, detailing a strategic asset acquisition and outlining key milestones for the remainder of 2026, including clinical trial initiations and data readouts.

Kairos Pharma, Ltd. presented an investor presentation at the 2026 LD Micro Invitational XVI, providing updates on its clinical program and partnering activities.

Kairos Pharma, Ltd. has entered into a binding term sheet to acquire worldwide rights to CL-273, an AI-designed pan-EGFR inhibitor for lung cancer, from Celyn Therapeutics, Inc.

Kairos Pharma reports a net loss of $1.65 million for Q1 2026 as it continues clinical development of its oncology pipeline.

Kairos Pharma, an early-stage biotech, reported increased net losses in Q3 2025 while securing significant financing to advance its oncology immunotherapy and cell therapy programs.

Kairos Pharma, a clinical-stage biopharmaceutical company, reported significantly increased net losses and cash burn for the first half of 2025, while successfully securing over $3.9 million in new financing.

Kairos Pharma's Q1 2025 report reveals ongoing clinical trials and a recent private financing aimed at advancing its cancer therapeutics.

Kairos Pharma amends executive employment agreements, secures a $30 million equity line of credit, and reports a net loss of $1.623 million for the nine months ended September 30, 2024, while also detailing various financial and operational updates.

Kairos Pharma, Ltd. filed an amendment to its 2024 Annual Report to include detailed information on executive compensation, corporate governance, and related party transactions, ensuring SEC compliance.

Kairos Pharma, Ltd. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted exhibits related to securities description and executive compensation recovery policy.

Kairos Pharma's 2024 10-K filing details the company's ongoing clinical trials, financial status, and strategic focus on developing cancer therapeutics.

Kairos Pharma's Chief Scientific Officer, Neil Bhowmick, was granted 171,756 restricted stock units under the company's 2023 Equity Incentive Plan.

Kairos Pharma Director Hyun W. Bae reported the acquisition of 29,084 Restricted Stock Units under the company's 2023 Equity Incentive Plan.

Kairos Pharma's VP of Research and Development, Murali Ramachandran, was granted 152,672 restricted stock units under the company's 2023 Equity Incentive Plan.

Kairos Pharma Director Hansoo Michael Keyoung received grants of 29,084 Restricted Stock Units under the company's equity incentive plan.

Kairos Pharma Director Rahul Singhvi acquired 19,084 restricted stock units, vesting fully on the first anniversary of the grant date.

Kairos Pharma's Chief Financial Officer, Doug Samuelson, was granted 152,672 restricted stock units under the company's 2023 Equity Incentive Plan.

Kairos Pharma has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, a reverse stock split, and equity plan amendments.

Kairos Pharma is seeking stockholder approval for several key proposals at its upcoming annual meeting, including the election of directors, ratification of auditors, and approval of an equity line of credit agreement.

Kairos Pharma announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory votes.

Kairos Pharma obtained majority stockholder approval to issue shares exceeding 19.99% of outstanding common stock to facilitate funding for clinical trials and general corporate purposes.

Kairos Pharma is registering shares for resale by Helena Global Investment Opportunities I Ltd., potentially raising up to $15 million through an equity line of credit agreement.

Kairos Pharma has filed a registration statement for the resale of 6.4 million shares of common stock, including shares underlying warrants issued in a recent private placement.

Kairos Pharma updates its IPO registration statement, detailing officer loan conversions to common stock and ongoing clinical trial funding.

Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering to advance its cancer therapeutics pipeline and list its stock on the NYSE American under the symbol KAPA.

Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering to advance its cancer therapeutics pipeline.

Kairos Pharma aims to raise capital through an initial public offering to fund clinical trials and further develop its pipeline of cancer therapeutics.

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Kairos Pharma, LTD. as of June 30, 2025.

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 9.99% beneficial ownership stake in Kairos Pharma, LTD., holding 1,696,924 shares of common stock.